Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Second Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers

NCT05206370 is registered in ClinicalTrials.gov with Achieve Life Sciences as lead sponsor.

NCT NCT05206370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05206370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Second Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers
Lead sponsor
Achieve Life Sciences
Phase
Phase 3
Overall status
Completed
Start date
January 20, 2022
Completion date
March 21, 2023
Enrollment
792 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation